<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/250149-novel-indole-derivatives-and-their-use-as-medicaments by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:35:49 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 250149:NOVEL INDOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL INDOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The general formula (1) the substituents should at least be R denotes a - Hydrogen - straight-chain or branched (C1-C6)-alkylcarbonyl - straight-chain or branched (C1-C6)-alkyloxycarbonyl R1 denotes - 5-,6-, 7-quinolyl - pyrido[2,3-b]pyrazinyl - indazolyl - isothiazolyl - indolyl - isoxazolyl optionally substituted by a (C1-C6) alkyl group or (C1-C6)-alkoxy group R2 denotes benzyl, substituted with halogen R3, R4 denote hydrogen Z1, Z2 denote O, S</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Novel indole derivatives and their use as medicaments<br>
The invention relates to novel indole derivatives of the general formula 1, to their<br>
preparation and to their use as medicaments, in particular for treating tumors.<br>
This invention has been divided out from the Parent Application No. 51/KOLNP/2003 of<br>
15.01.2003, Entitled: Novel indole derivatives and their use as medicaments.<br>
Indol-3-yl derivatives having certain 2-, 3-, 4- and 8- quinoline radicals are described in<br>
the German application DE 198 14 838.0. However, indol-3-yl derivatives having 5-, 6-<br>
or 7-quinoline substituents are neither described nor suggested in this publication.<br>
According to one aspect of the invention, novel indole derivatives of the general formula<br>
1<br><br>
in which<br>
R denotes hydrogen; straight-chain or branched (C1-C6) -alkyl; (C1-C6) -alkyl which is<br>
mono- or polysubstituted by aryl, where the aryl radical [lacuna] unsubstituted or<br>
mono- to penta-[lacuna] by identical or different substituents from the group<br>
consisting of halogen, (C1-C6) -alkyl, (C3-C7) -cycloalkyl, carboxyl, (C1-C6) -<br>
alkoxy-carbonyl, preferably tert-butoxycarbonyl, straight-chain or branched (C1-C6) -<br>
alkyl, which is substituted by one or more fluorine atoms,<br><br>
preferably trifluoromethyi, hydroxyl, straight-<br>
chain or branched (C1-C6)-alkoxy, preferably<br>
methoxy or ethoxy; benzyloxy or aryl-(C1-C6)-alkyl,<br>
where the aryl radical may be unsubstituted or<br>
mono- or pentasubsti tuned by identical or<br>
different substituents from the group consisting<br>
of (C1-C6)-alkyl, halogen and straight-chain or<br>
branched (C1-C6)-alkyl which is substituted by one<br>
or more fluorine atoms, preferably<br>
trifluoromethyi; straight-chain or branched (C1-<br>
C6)-alkoy-(C1-C6)-alkyl [sic], substituted or<br>
unsubstituted aryl- (C1-C6) -alkyloxycarbonyl,<br>
preferably benzyloxycarbonyl, straight-chain or<br>
branched (C1-C6)-alkyloxycarbonyl, straight-chain<br>
or branched (C1-C6)-alkylcarbonyl, preferably<br>
acetyl, (C2-C6)-alkenyl, preferably allyl, (C2-C6)-<br>
alkynyl, preferably ethynyl or propargyl, or<br>
straight-chain or branched cyano-(C1-Ce)-alkyl,<br>
preferably cyanomethyl;<br>
denotes a saturated, unsaturated or aromatic<br>
(C2-C14)-heterocycle which contains one or more<br>
heteroatoms selected from the group consisting of<br>
N, 0 and S and which may be attached to the amide<br>
nitrogen directly or via a (C1-C6)-alkyl bridge,<br>
where the (C1-C4) -alkyl radical may be<br>
unsubstituted or mono- [lacuna] polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-C6)-alkyl, halogen and oxo (=0)<br>
and the 2-, 4-, 5- or 6-pyrimidinyl radical may in<br>
each case be unsubstituted or mono- to<br>
trisubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1—C6) -alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (C1-C6) -alkylamino,<br>
hydroxyl, (C1-C6)-alkoxy, benzyloxy, carboxyl,<br>
(C1-C6)-alkoxycarbonyl, (C1-C6)-alkoxycarbonylamino<br>
or (C:~C6)-alkyl which is mono- or polysubstituted<br>
by fluorine, preferably trifluoromethyi, (C6-C10 -<br><br>
aryl and (C6-C10) -aryl- (C1-C6) -alkyl, with the<br>
proviso that Rl does not represent unsubstituted<br>
2- or 4-pyrimidinyl or a 2-pyrimidinyl radical<br>
which is mono- or polysubstituted by methyl; and<br>
except for (C1-C6)-alkyl-, halogen-, nitro-,<br>
amino- and (C1-C6)-alkylamino-substituted or<br>
unsubstituted 2-, 3-, 4- and 8-quinolyl and 2-, 3-<br>
and 4-quinolylmethyl in which the ring carbon<br>
atoms of the pyridylmethyl moiety are<br>
unsubstituted or substituted by (C1-C6)-alkyl,<br>
(C1-C6)-alkoxy, nitro, amino and (C1-C6)-<br>
alkoxycarbonylamino;<br>
R2 denotes hydrogen, (C1-C6 -alkyl, (C1-C6)-alkyl<br>
which is mono- or polysubstituted by halogen, (C1-<br>
C6)-alkyl which is mono- or polysubstituted by<br>
phenyl, where the phenyl radical may be<br>
unsubstituted or nono- to pentasubstituted by<br>
identical or different substituents from the group<br>
consisting of halogen, preferably chlorine,<br>
bromine or iodine, (C1-C6) -alkyl, (C3-C7)-<br>
cycloalkyl, carboxyl, (C1-C6) -alkoxycarbonyl, (C1-<br>
C6)-alkyl which is mono- or polysubstituted by<br>
halogen, preferably trifluoromethyl, hydroxyl,<br>
(C1-C6)-alkoxy, preferably methoxy or ethoxy,<br>
phenyl-(C1-C6)-alkoxy, preferably benzyloxy, nitro,<br>
amino, mono-(C1-C6)-alkylamino, di-(C1-C6)-<br>
alkylamino, mono- (C2-5) -cycloalkylamino, di-(C3-6)-<br>
cycloalkylamino, (C1-C6) -acylamino, phenyl- (C1-C6) -<br>
alkylamino, arylcarbonylamino, heteroarylcarbonyl-<br>
amino, (C1-C6) -alkylsulfonamido, arylsulfonamido,<br>
maleinimido, succinimido, phthalimido, benzyl-<br>
oxycarbonylamino (Z-amino), tert-butoxy-<br>
carbonylamino (BOC-amino), 9-fluorenylmethoxy-<br>
carbonylamino (Fmoc-amino), triphenylmethylamino<br>
(Tr-amino) , 2-(4'-pyridyl)-ethoxycarbonylamino<br>
(Pyoc-amino) , diphenylmethylsilylamino (DPMS-<br>
amino), by -NH-CH2-COOH; -NH-CH (CH3)-COOH;<br><br>
(CH3)2CH-CH2-CH2-CH(NH-)-COOH; H3C-CH2-CH (CH3)-<br>
CH(NH-)-COOH;<br>
H0H2C-CH(NH-)-C0OH; phenyl-CH2-CH (NH- ) -COOH; (4-<br>
imidazolyl)-CH2-CH(NH-)-COOH; HN=C (NH2) -NH- (CH2)3-<br>
CH(NH-)-COOH; H2N-(CH2)4-CH(NH-)-COOH;<br>
H2N-CO-CH2-CH (NH-) -COOH; HOOC- (CH2) 2-CH (NH-) -COOH;<br>
a 2-, 3-, 4-, 5-, 6-, 7- and 8-quinolyl-(C:-C6) -<br>
alkyl radical, where the 2-, 3-, 4-, 5,-, [sic]<br>
6-, 7- and 8-quinolyl radical may be unsubstituted<br>
or mono- to hexasubstituted by identical or<br>
different substituents from the group consisting<br>
of halogen, (C1-C4)-alkyl or (C:-C4) -alkoxy;<br>
a 2~, 3- and 4-pyridyl-(C:-C6&gt;-alkyl radical, where<br>
the 2-, 3- and 4-pyridyl radical may be<br>
unsubstituted or mono- to tetrasubstituted by<br>
identical or different substituents from the group<br>
consisting of halogen, (C1-C4)-alkyl and (C-_-C4)-<br>
alkoxy;<br>
an arylcarbonyl radical, where the aryl radical<br>
may be unsubstituted or mono- to pentasubstituted<br>
by identical or different substituents from the<br>
group consisting of halogen, (C1-Cs) -alkyl, (C3-<br>
C7)-cycloalkyl, carboxyl, cyano, (C1-C6)-<br>
alkoxycarbonyl, (C1-C6) -alkyl which is mono- or<br>
polysubstituted by fluorine atoms preferably<br>
trifluoromethyl, hydroxyl, (C1-C4) -alkoxy<br>
preferably methoxy or ethoxy, aryl- (C1-C4) -alkoxy,<br>
preferably benzyioxy;<br>
R;. and R4 may be attached to the indole carbon atoms<br>
C-2, C-4, C-5, C-6 or C-7 and independently of one<br>
another denote hydrogen, hydroxyl, (C1-C6)-alkyl,<br>
(C3-C7) -cycloalkyl, (d-C6)-alkylcarbonyl, (C:-C5)-<br>
alkoxy, halogen, aryl-(C1-C4)-alkoxy, preferably<br>
benzyioxy, nitro, amino, mono-(C;-C4)-alkylamino,<br>
di- (C1-C4) -alkylarr.ino, (C:-C6) -alkoxycarbonylamino ,<br>
(C1-C6) -alkoxycarbonylamino- (C1-Ce) -alkyl, cyano,<br>
straight-chain or branched cyano- (C1-C6) -alkyl,<br>
carboxyl, (C2-C4) -alkoxycarbonyl, (C1-C4) -alkyl<br><br>
which , is .substituted by one or more fluorine<br>
atoms, preferably trifluoromethyl group, carboxy-<br>
(C:-C6)-alkyl or (C:-C5) -alkoxycarbonyl- lCi-C6) -<br>
alkyl;<br>
Z: denotes oxygen or sulfur or geminally attached<br>
hydrogen and hydroxyl;<br>
Zi denotes oxygen or sulfur,<br>
their tautomers, stereoisomers, including	the<br>
diastereomers and enantiomers, and	the<br>
physiologically acceptable salts thereof,	are<br>
provided.<br>
Thus, for example, the compounds of the general formula<br>
(1) according to the invention which have one or more<br>
centers of chirality and which are present as racemates<br>
can be separated by methods known per se into their<br>
optical isomers, i.e. enantiomers or diastereomers. The<br>
separation can be carried out by column separation on<br>
chiral phases or by recrystallization from an optically<br>
active solvent or using an optically active acid or<br>
base or by derivatization with an optically active<br>
reagent, such as, for example, an optically active<br>
alcohol, and subsequent removal of the radical.<br>
Furthermore, the indole derivatives of the formula (1)<br>
according to the invention can be converted into their<br>
salts with inorganic or organic acids, in particular,<br>
for pharmaceutical use, into their physiologically<br>
acceptable salts. Acids which are suitable for this<br>
purpose are, for example, hydrochloric acid,<br>
hydrobromic acid, sulfuric acid, phosphoric acid,<br>
fumaric acid, succinic acid, lactic acid, malic acid,<br>
eribonic acid, malonic acid, citric acid, acetic acid,<br>
tartaric acid, trifluoroacetic acid, methanesulfonic<br>
acid, sulfoacetic acid or maleic acid.<br><br>
Moreover, the compounds of the formula (1) according to<br>
the invention can, if they contain a sufficiently-<br>
acidic group, such as a carboxyl group, be converted,<br>
if desired,.into their salts with inorganic or organic<br>
bases, in particular, for pharmaceutical use, into<br>
their physiologically acceptable salts. Bases which are<br>
suitable for this purpose are, for example, sodium<br>
hydroxide, potassium hydroxide, calcium hydroxide,<br>
lysine, cyclohexylamine, ethanolamine, diethanolamine<br>
and triethanolamine.<br>
According to a preferred embodiment, indole derivatives<br>
of the general formula (1) above are provided in which<br>
R, R2, R3, R4, Zl and Z2 have the meanings given above<br>
and<br>
R: denotes a 2-, 4-, 5- or 6-pyrimidinyl radical or<br>
2-, 4-, 5- or 6-pyrimidinyl-(C:-C4)-alkyl radical,<br>
where the {C1-C4) -alkyl radical may be<br>
unsubstituted or mono- [lacuna] polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-Ce) -alkyl, halogen and oxo (=0)<br>
and the 2-, 4-, 5- or 6-pyrimidinyl radical may be<br>
unsubstituted or mono- to trisubstituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-Cs)-alkyl, halogen,<br>
nitro, amino, mono- (C:-C£) -alkylamino, di-(.Ci-Cs) -<br>
alkylamino, hydroxyl, (C;-Co)-alkoxy, benzyloxy,<br>
carboxyl, (d-C6) -alkoxycarbonyl, (C:-C6)-<br>
alkoxycarbonylamino or (C1-Cs) -alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trif luoromethyl, (C0-C10)-aryl, or (C—Cio) -aryl-<br>
(C1-Ce)-alkyl, with the proviso that Rl does not<br>
represent unsubstituted 2- or 4-pyrimidinyl or a<br>
2-pyrimidinyl radical which is mono- or<br>
polysubstituted by methyl;<br>
a 3-, 4-, 5- or 6-pyridazinyl radical or 3-, 4-,<br>
5- or 6-pyridazinyl-(C1-C4)-alkyl radical, where<br>
the (C1-C4)-alkyl radical may be unsubstituted or<br><br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of (C:-C;)-<br>
alkyl, halogen and oxo (=0) and the 3-, 4-, 5- or<br>
6-pyridazinyl radical may . be unsubstituted or<br>
mono- to trisubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-Cs)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (C1-Ce) -alkylamino,<br>
hydroxyl, (C1-Ce)-alkoxy, benzyloxy, carboxyl, (C:-<br>
Co) -alkoxycarbonyl, (C:-C6) -alkoxycarbonylamino or<br>
(C1-Co)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C5-C10)-aryl<br>
and (C6-Cio) -aryl- (C1-C6) -alkyl;<br>
a 2-, 3-, 5- or 6-pyrazinyl radical or 2-, 3-, 5,-<br>
[sic] or 6-pyrazinyl-(d-C4)-alkyl radical, where<br>
the (C1-C4)-alkyl radical may be unsubstituted or<br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of (C:-C5)-<br>
alkyl, halogen and oxo (=0) and the 2-, 3-, 5,-<br>
[sic] or 6-pyrazinyl radical may be unsubstituted<br>
or mono- to trisubstituted by identical or<br>
different substituents from the group consisting<br>
of hydrogen, (C1-C6)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (C1-C6) -alkylamino,<br>
hydroxyl, (C1-Ce)-alkoxy, benzyloxy, carboxyl, (C1-<br>
C6) -alkoxycarbonyl, (C1-C0) -alkoxycarbonylamino or<br>
(C1-Ce)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C6-Cio)-aryl<br>
and (C6-C:3) -aryl- (C1-Ce) -alkyl ;<br>
a 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl radical or<br>
3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-(C1-C4)-alkyl<br>
radical, where the (C^-C^)-alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (Cx-C?)-alkyl, halogen and oxo (=0)<br>
and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl<br>
radical may be unsubstituted or mono- to<br>
pentasubstituted by identical or different<br>
substituents from the group consisting of<br><br>
hydrogen, (C1-C6)-alkyl, halogen, nitro, amino,<br>
. mono- (C1-C6) -alkylamino, di- (C1-C-) -alkylamino,<br>
hydroxyl, (C1-C5) -alkoxy, benzyloxy, carboxyl, (d-<br>
C6)-alkoxycarbonyl, (C:-Cf)-alkoxycarbonylamino or<br>
(C1-C6)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C5-C:o) -aryl<br>
and (C6-C10)-aryl-(C1-C6)-alkyl;<br>
a 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl radical or<br>
2-, 4-, 5-, 6-, 7- or 8-quinazolinyl-(C1-C4)-alkyl<br>
radical, where the (C:-C4)-alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-Cs) -alkyl, halogen and<br>
oxo (=0) and the or [sic] 2-, 4-, 5-, 6-,, 7- or<br>
8-quinazolinyl radical, may be unsubstituted or<br>
mono- to pentasubstituted by identical or<br>
different substituents from the group consisting<br>
of hydrogen, (CN-Ce)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C5) -alkylamino, di- (d-C;) -alkylamino,<br>
hydroxyl, (C1-C6)-alkoxy, benzyloxy, carboxyl, (C1-<br>
Ce) -alkoxycarbonyl, (C:-C£) -alkoxycarbonylamino or<br>
(C1-C6)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C6-Ci0)-aryl<br>
and (C6-Cio)-aryl- (C1-C«) -alkyl;<br>
a 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl radical or<br>
2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl-(C1-C4)-alkyl<br>
radical, where the (C:-C
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-Cs) -alkyl, halogen and oxo (=0)<br>
and the or [sic] 2-, 3-, 5-, 6-, 7- or 8-<br>
quinoxalinyl radical may be unsubstituted or mono-<br>
to pentasubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C-.-C^)-alkyl, halogen, nitro, amino,<br>
mono- (C:-C6) -alkylamino, di- (C:-C6) -alkylamino,<br>
hydroxyl, (C:-C6) -alkoxy, benzyloxy, carboxyl, (C:-<br>
C6) -alkoxycarbonyl, (C1-C6)-alkoxycarbonylamino or<br>
(C1-C5)-alkyl which is mono- or polysubstituted by<br><br>
fluorine, preferably trifluoromethyl, (C6-C10)-aryl<br>
and (Co-Cn) -aryl- (C1-C6) -alkyl ;<br>
a 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl radical or<br>
1-, 4-, 5-, 6-, 7- or 8-phthalazinyl- (C:-C4) -alkyl<br>
radical, where the (C1-C4) -alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-Cg) -alkyl, halogen and oxo (=0)<br>
and the or [sic] 1-, 4-, 5-, 6-, 7- or 8-<br>
phthalazinyl radical may be unsubstituted or mono-<br>
to pentasubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C-^-Ce) -alkyl, halogen, nitro, amino,<br>
mono- (C1-Co) -alkylamino, di- (C1-Ce) -alkylamino,<br>
hydroxyl, (C1-C5) -alkoxy, benzyloxy, carboxyl, (Cx-<br>
C6) -alkoxycarbonyl, (CN-Co) -alkoxycarbonylamino or<br>
(C1-Cs)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (Cj-Ci;)-aryl<br>
and (C6-C::.) -aryl- (C:-C6) -alkyl;<br>
a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical or<br>
2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl- (C1-C4) -alkyl<br>
radical, where the (C1-C4)-alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-Cs) -alkyl, halogen and oxo (=0)<br>
and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl<br>
radical may be unsubstituted or mono- to<br>
hexasubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (d-C6) -alkyl, preferably methyl,<br>
particularly preferably 2-methyl, halogen, nitro,<br>
amino, mono- (C1-Cs) -alkylamino, N, N-di- (C1-C6) -<br>
alkylamino, hydroxyl, (C1-C6)-alkoxy, (C6-C14)-<br>
aryl-(C1-C6)-alkyoxy [sic], preferably benzyloxy,<br>
carboxyl, (C1-C6)-alkoxycarbonyl, (C:-C;)-<br>
alkoxycarbonylamino or (C:-C-;) -alkyl which is mono-<br>
or polysubstituted by halogen, preferably<br>
trifluoromethyl, (C6-Ci4)-aryl and (C6-Ci4)-aryl-<br>
(C1-C6)-alkyl, except for (C1-C6)-alkyl-, halogen-,<br><br>
nitro-, amino- and (C1-C6)-alkylamino-substituted<br>
or unsubstituted 2-, 3-, 4- and 8-quinolyl and 2-,<br>
3- and 4-quinolylmethyl in which the ring carbon<br>
atoms of the pyridylmethyl moiety are<br>
unsubstituted or substituted by (C1-C6)-alkyl,<br>
(C1-C6)-alkoxy, nitro, amino and (C1-C6)-<br>
alkoxycarbonylamino;<br>
a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical<br>
or 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl-(C1-CJ -<br>
alkyl radical, where the (C1-C4)-alkyl radical may<br>
be unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-C6) -alkyl, halogen and oxo (=0)<br>
and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl<br>
radical may be unsubstituted or mono- to<br>
hexasubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-C.5)-alkyl, halogen, nitro, amino,<br>
mono- (C1-Ce) -alkylamino, di- (C:-Cs) -alkylarr.ino,<br>
hydroxyl, (C1-C6) -alkoxy, benzyloxy, carboxyl, (C--<br>
Ce) -alkoxycarbonyl, (C1-Ce) -alkoxycarbonylamino or<br>
(C:-C6)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (Ce-Cio)-aryl<br>
and (C6-Cio) -aryl- (C1-Ce) -alkyl;<br>
a 2-, 6-, 8- or 9- [9H] -purinyl radical or 2-, 6-,<br>
8- or 9-[9H]-purinyl-(C1-C4)-alkyl radical, where<br>
the (C1-C4)-alkyl radical may be unsubstituted or<br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of (C1-C5)-<br>
alkyl, halogen and oxo (=0) and the 2-, 6-, 8- or<br>
9-[9H] -purinyl radical may be unsubstituted or<br>
mono- to trisubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C—Ce)-alkyl, halogen, nitro, amino,<br>
mono- (C-.-Cs) -alkylamino, di- (C:-C.O -alkylamino,<br>
hydroxyl, (C-L-Co) -alkoxy, benzyloxy, carboxyl, (C-_-<br>
CA)-alkoxycarbonyl, (C1-C6)-alkoxycarbonylamino or<br>
(C;-Ce)-alkyl which is mono- or polysubstituted by<br><br>
fluorine, preferably trifiuoromethyl, (C6-Cio) -aryl<br>
and (C6-C::)-aryl- (C:-C6) -alkyl;<br>
a 2-, 6-, 7- or 8- [1H] -purinyl radical or 2-, 6-,<br>
7- or 8-[7tf]-purinyl-(d-d)-alkyl radical, where<br>
the . (C1-C4)-alkyl radical may be unsubstituted or<br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of (C1-C6)-<br>
alkyl, halogen and oxo (=0) and the 2-, 6-, 7- or<br>
8-[1H] -purinyl radical may be unsubstituted or<br>
mono- to trisubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (d~d)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (d-d) -alkylamino,<br>
hydroxyl, (d-C6) -alkoxy, benzyloxy, carboxyl, (d~<br>
C6)-alkoxycarbonyl, (C1-C6) -alkoxycarbonylamino or<br>
(C1-C0) -alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trif Iuoromethyl, (d~Cio) -aryl<br>
and (C6-Ci0)-aryl- (C1-C6) -alkyl;<br>
a 1-, 2-, 3-, 4~, 5-, 6-, 7-, 8- or 9-acridinyl<br>
radical or 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or<br>
9-acridinyl-(C1-C4)-alkyl radical, where the (d-<br>
C6)-alkyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-Cg)-<br>
alkyl, halogen and oxo (=0) and the 1-, 2-, 3-,<br>
4-, 5-, 6-, 7-, 8- or 9-acridinyl radical may be<br>
unsubstituted or mono- to octasubstituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-C5)-alkyl, halogen,<br>
nitro, amino, mono- (C1-Ce) -alkylamino, di-(C:-C6)-<br>
alkylamino, hydroxyl, (C1-C6)-alkoxy, benzyloxy,<br>
carboxyl, (C1-C6) -alkoxycarbonyl, (C1-C6)-<br>
alkoxycarbonylamino or (C-.-Ce) -alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trif Iuoromethyl, (C5-C:o) -aryl and (C6-C;;:) -aryl-<br>
(C-_-C0) -alkyl;<br>
a 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9- or<br>
10-phenanthridinyl radical or 1-, 2-, 3-, 4-, 6-,<br>
7-, 8- or 9- or 10-phenanthridinyl- (C1-C6) -alkyl<br><br>
radical, where the (C:-C6) -alkyl radical may be<br>
, unsubstituted or mono- or polysubstiluted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C:-Ci)-alkyl, halogen and<br>
oxo (=0) and the 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9- or<br>
10-phenanthridinyl radical may be unsubstituted or<br>
mono- to octasubstituted by identical or different<br>
substituents from the group consisting of (C1-Cg)-<br>
alkyl, halogen, nitro, amino, mono-(C1-Ce) -<br>
alkylamino, di- (C1-Cg)-aikylamino, hydroxyl, (Cx-<br>
C5)-alkoxy, (C6-C:o)-aryl-(C:-C6)-alkoxy, preferably<br>
benzyloxy, carboxyl, (C:-C6)-alkoxycarbonyl, (C1-<br>
C6) -alkoxy car bony 1 ami no or (C1-Ce) -alkyl which is<br>
mono- or polysubstituted by fluorine, preferably<br>
trifluoromethyl, (C6-Ci0)-aryl and (C6-Ci0) -aryl-<br>
(C1-C6)-alkyl;<br>
a 2-, 3-, 4-, 5,- [sic] or 6-pyridyl radical where<br>
the 2-, 3-, 4-, 5,- [sic] or 6-pyridyl radical may<br>
be unsubstituted or mono- to tetrasubscituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-Ce)-alkyl, halogen,<br>
nitro, amino, mono-(C1-C5)-alkylamino, di-fCi-Ce)-<br>
alkylamino, hydroxyl, (C1-Ce)-alkoxy, benzyloxy,<br>
carboxyl, (d-C6) -alkoxycarbonyl, (C1-C6)-<br>
alkoxycarbonylamino or (C1-Cg)-alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trifluoromethyl, (C6-Cio)-aryl and (Cr--C;;)-aryl-<br>
(C1-C6)-alkyl, with the proviso that zi# Z;, R2, R3<br>
and R4 have the meaning given above or below,<br>
without any limitations, and R represents (C2-C0)-<br>
alkenyl, preferably allyl, (C2-C6)-alkynyl,<br>
preferably ethynyl or propargyl, (C1-C*)-alkoxy-<br>
(C1-C6)-alkyl, or straight-chain or branched cyano-<br>
(C1-C6) -alkyl, preferably cyanomethyl, cr with the<br>
proviso that Z2, R, R-, R3 and R.; have the meanings<br>
described above or below, without any limitations,<br>
and Zi denotes geminally attached hydrogen and<br>
hydroxyl;<br><br>
a 2-, 3-, 4-, 5,- [sic] or 6-pyridyi-(C:-C6)-alkyl<br>
radical, where the (C:-C£)-alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-C5)-alkyl, halogen and oxo (=0)<br>
and the 2-, 3-, 4-, 5,- [sic] or 6-pyridyl radical<br>
may be unsubstituted or mono- to tetrasubstituted<br>
by identical or different substituents from the<br>
group consisting of hydrogen, (C1-C0) -alkyl,<br>
halogen, nitro, amino, mono-(C:-Cg)-alkylamino, di-<br>
(C:-C6)-alkylamino, hydroxyl, (C:-C;) -alkoxy,<br>
benzyloxy, carboxyl, (C1-Cg)-alkoxycarbonyl, (C:-<br>
C6)-alkoxycarbonylamino or (C1-C6) -alkyl which is<br>
mono- or polysubstituted by fluorine, preferably<br>
trifluoromethyl, (C6-C;o)-aryl and (C6-C10) -aryl-<br>
(C1-C6)-alkyl;<br>
a 2-, 3-, 4,- [sic] or 5-thienyl radical or 2-,<br>
3-, 4,- [sic] or 5-thienyl- (C1-C6) -alkyl radical,<br>
where the (C;-C--)-alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-Cs) -alkyl, halogen and oxo (=0)<br>
and the 2-, 3-, 4,- [sic] or 5-thienyl radical may<br>
be unsubstituted or mono- to trisubstituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-Ce)-alkyl, halogen,<br>
nitro, amino, mono- (C:-Cf) -alkylamino, di-(C1-Cs)-<br>
alkylamino, hydroxyl, (C1-C6)-alkoxy, benzyloxy,<br>
carboxyl, (C:-C6)-alkoxycarbonyl, (C1-Cs)-<br>
alkoxycarbonylamino or (C;-C6) -alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trifluoromethyl, (C5-C1:.) -aryl and (C6-Cio) -aryl-<br>
(C:-C5)-alkyl;<br>
a 2-, 4-, or 5-thiazolyl radical or 2-, 4-, or 5-<br>
thiazolyl-(C1-Cf)-alkyl radical, where the (C1-C3)-<br>
aikyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-Ce)-<br>
alkyl, halogen and oxo (=0) and the 2-, 4-, or 5-<br><br>
thiazolyl' radical may be unsubstituted or mono- or<br>
disubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (d-C6) -alkyl, halogen, nitro, amino,<br>
mono- (C;-C6) -alkylamino, di- (C:-C6) -alkylamino,<br>
hydroxyl, (C1-Cs) -alkoxy, benzyloxy, carboxyl, (C1-<br>
C6)-alkoxycarbonyl, (C1-Cs)-alkoxycarbonylamino or<br>
(C1-Ce) -alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (Ce-Cio)-aryl<br>
and (C£-Cio)-aryl-(C1-Ce)-alkyl;<br>
a 3-, 4-, or 5-isothiazolyl radical or 3-, 4- or<br>
5-isothiazolyl-(C1-C6)-alkyl radical, where the<br>
(C1-Ce)-alkyl radical may be unsubstituted or mono-<br>
or polysubstituted by identical or different<br>
substituents from the group consisting of (C1-Cg)-<br>
alkyl, halogen and oxo (=0) and the 3-, 4- or 5-<br>
isothiazolyl radical may be unsubstituted or mono-<br>
or disubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-Ce)-alkyl, halogen, nitro, amino,<br>
mono- (C1-Ce) -alkylamino, di- (C1-Ce) -alkylamino,<br>
hydroxyl, (C1-C6)-alkoxy, benzyloxy, carboxyl, (C1-<br>
Ce)-alkoxycarbonyl, (C1-C6)-alkoxycarbonylamino or<br>
(C:-C6)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (Cg-Cio)-aryl<br>
and (Cf-Cio) -aryl- (Cx-C6) -alkyl;<br>
a 2-, 4-, 5-, 6- or 7-benzothiazolyl radical or<br>
2-, 4-, 5-, 6- or 7-benzothiazolyl- (C--Cs) -alkyl<br>
radical, where the (C1-C6) -alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-Ce) -alkyl, halogen and oxo (=0)<br>
and the 2-, 4-, 5-, 6- or 7-benzothiazolyl radical<br>
may be unsubstituted or mono- to tetrasubstituted<br>
by identical or different substituents from the<br>
group consisting of hydrogen, (C^-Ce)-alkyl,<br>
halogen, nitro, amino, mono-(C1-Ce)-alkylamino, di-<br>
(C:-Co) -alkylamino, hydroxyl, (C1-C6) -alkoxy,<br>
benzyloxy, carboxyl, (C1-Ce)-alkoxycarbonyl, (C;-<br><br>
C6&gt; -alkoxycarbonylamino or (d~d) -alkyl which is<br>
mono- or. polysubstituted by fluorine, preferably<br>
trifluoromethyl, (C6-Cio) -aryl and (d~do) -aryl-<br>
(C^Ce)-alkyl;.<br>
a 1-, 2-, 4- or 5-imidazolyl radical or 1-, 2-, 4-<br>
or 5-imidazolyl-(C1-C6&gt;-alkyl radical, where the<br>
(C1-C6)-alkyl radical may be unsubstituted or mono-<br>
or polysubstituted by identical or different■<br>
substituents from the group consisting of (d~d)-<br>
alkyl, halogen and oxo (=0) and the 1-, 2-, 4- or<br>
5-imidazolyl radical may be unsubstituted or mono-<br>
to trisubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (d~d)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (d~d) -alkylamino,<br>
hydroxyl, (d~d)-alkoxy, benzyloxy, carboxyl, (d~<br>
d)-alkoxycarbonyl, (d_d)-alkoxycarbonylamino or<br>
(d~d) -alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (d-d:)-aryl<br>
and (Cs-Cio) -aryl- (C;-C6) -alkyl;<br>
a 1-, 3-, 4- or 5-pyrazolyl radical or 1-, 3-, 4-<br>
or 5-pyrazolyl-(C1-C6)-alkyl radical, where the<br>
(C1-C6)-alkyl radical may be unsubstituted or mono-<br>
or polysubstituted by identical or different<br>
substituents from the group consisting of (C1-C6)-<br>
alkyl, halogen and oxo (=0) and the 1-, 3-, 4- or<br>
5-pyrazolyl radical may be unsubstituted or mono-<br>
to trisubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-Ce)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (d-C6) -alkylamino,<br>
hydroxyl, (C1-C6) -alkoxy, benzyloxy, carboxyl, (d-<br>
C6) -alkoxycarbonyl, (C1-C6) -alkoxycarbonylamino or<br>
(d-d)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C^-C—.)-aryl<br>
and (C6-Cio) -aryl- (C:-C6) -alkyl;<br>
a 1-, 2,- [sic] 3,- [sic] 4,- [sic] or 5-pyrroiyl<br>
radical or 1-, 2,- [sic] 3,- [sic] 4,- [sic] or<br>
5-pyrrolyl-(C1-C6)-alkyl radical, where the (d-<br><br>
C6)-alkyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-C6)-<br>
alkyl, halogen and oxo (=0) and the 1-, 2,- [sic]<br>
3,- [sic] 4,- [sic] or 5-pyrrolyl radical may be<br>
unsubstituted or mono- to tetrasubstituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-Ce)-alkyl, halogen,<br>
nitro, amino, mono- (C1-C6&gt; -alkylamino, di-(C1-C6&gt;-<br>
alkylamino, hydroxyl, (C:-C6)-alkoxy, benzyloxy,<br>
carboxyl, (C1-Ce) -alkoxycarbonyl, (C:-C5)-<br>
alkoxycarbonylamino or (C:-Cg)-alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trif luoromethyl, (C6-Cio)-aryl and (C6-Cio) -aryl-<br>
(d-C6)-alkyl;<br>
a 1-, 3-, or 5-[1.2.4]-triazolyl radical or 1-, 3-<br>
or 5-[1.2.4]-triazolyl-(C1-Cc)-alkyl radical, where<br>
the (C1-C6) -alkyl radical may be unsubstituted or<br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-Ce) -alkyl, halogen and oxo (=0) and<br>
the 1-, 3- or 5-[1.2.4]-triazolyl radical may be<br>
unsubstituted or mono- or disubstituted by<br>
identical or different substituents from the group<br>
consisting of (C:-C6)-alkyl, halogen, nitro, amino,<br>
mono- (C1-Ce) -alkylamino, di- (C1-C6) -alkylamino,<br>
hydroxyl, (C1-C6)-alkoxy, benzyloxy, carboxyl, (C1-<br>
Ce)-alkoxycarbonyl, (C:-C5)-alkoxycarbonylamino or<br>
(C1-Cj)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (Ce-C10)-aryl<br>
and (C6-Cio) -aryl- (C1-C6) -alkyl;<br>
a 1-, 4- or 5-[l.2.3]-triazolyl radical or 1-, 4-<br>
or 5-[1.2.3]-triazolyl-(C1-C6)-alkyl radical, where<br>
the (C1-Ce)-alkyl radical may be unsubstituted or<br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of (C;-Ce)-<br>
alkyl, halogen and oxo (=0) and the 1-, 4- or 5-<br>
[1.2.3]-triazolyl radical may be unsubstituted or<br>
mono- or disubstituted by identical or different<br><br>
substituents . from the group consisting of<br>
hydrogen, (C:-C£&gt;-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (C1-C6) -alkylamino,<br>
hydroxyl, (C1-Ce) -alkoxy, benzyloxy, carboxyl, (C1-<br>
Ce)-alkoxycarbonyl, (C1-Ce)-alkoxycarbonylamino or<br>
(C1-Ce)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (Co-Cio)-aryl<br>
and (C6-C10)-aryl-(C1-C6)-alkyl;<br>
a 1- or 5-[lH]-tetrazolyl radical or 1- or 5-[ltf]-<br>
tetrazolyl-(C1-Ce)-alkyl radical, where the (C1-<br>
Ce)-alkyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-Cs)-<br>
alkyl, halogen and oxo (=0) and the 1- or 5-[lH]-<br>
tetrazolyl radical may be unsubstituted or<br>
substituted by hydrogen, (C1-C6&gt; -alkyl, halogen,<br>
nitro, amino, mono- (C1-Ce) -alkylamino, di-(C1-Ce)-<br>
alkylamino, hydroxyl, (C1-Cg)-alkoxy, benzyloxy,<br>
carboxyl, (C:-C6)-alkoxycarbonyl, (Ci.-Co)-<br>
alkoxycarbonylamino or (C1-C5)-alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trif luoromethyl, (C6-Ci0) -aryl and (C6-Cio) -aryl-<br>
(C1-Cs)-alkyl;<br>
a 2- or 5-[2H] -tetrazolyl radical or 2- or 5-[2H]-<br>
tetrazolyl-(C1-Ce)-alkyl radical, where the (C1-<br>
Ce)-alkyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-C6&gt;-<br>
alkyl, halogen and oxo (=0) and the 2- or 5-[2H]-<br>
tetrazolyl radical may be unsubstituted or<br>
substituted by hydrogen, (C1-Ce)-alkyl, halogen,<br>
nitro, amino, mono- (C1-C6&gt; -alkylamino, di-(C1-C6)-<br>
alkylamino, hydroxyl, (C1-C6)-alkoxy, benzyloxy,<br>
carboxyl, (C1-Ce) -alkoxycarbonyl, (C1-C6)-<br>
alkoxycarbonylamino or (C;-Ce)-alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trif luoromethyl, (Cs-Cio)-aryl and (Ce-C—)-aryl-<br>
(Cx-Cs) -alkyl;<br><br>
a 2-, 4- or 6-[1.3 .5]-triazinyl radical or 2-, 4-<br>
or 6-[1.3.5]-triazinyl-(C1-C6)-alkyl radical, where<br>
the (C1-C6) -alkyl radical may be unsubstituted or<br>
mono- or polysubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-C6)-alkyl, halogen and oxo (=0) and<br>
the 2-, 4- or 6-[1.3 . 5]-triazinyl radical may be<br>
unsubstituted or mono- or disubstituted by<br>
identical or different substituents from the group<br>
consisting of hydrogen, (C1-C5)-alkyl, halogen,<br>
nitro, amino, mono- (C1-C6) -alkylamino, di-(C1-Cs)-<br>
alkylamino, hydroxyl, (C-.-Cs)-alkoxy, benzyloxy,<br>
carboxyl, (C1-C6)-alkoxycarbonyl, (C1-C6)-<br>
alkoxycarbonylamino or (C1-C5)-alkyl which is mono-<br>
or polysubstituted by fluorine, preferably<br>
trifluoromethyl, (C6-C10) -aryl and (Ce-Cio) -aryl-<br>
(C1-C6&gt;-alkyl;<br>
a 2-, 4- or 5-oxazolyl radical or 2-, 4- or 5-<br>
oxazolyl-(C1-C6)-alkyl radical, where the (C:-Cs)-<br>
alkyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-Ce)-<br>
alkyl, halogen and oxo (=0) and the 2-, 4-, or 5-<br>
oxazolyl radical may be unsubstituted or mono- or<br>
disubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C:~C6)-alkyl, halogen, nitro, amino,<br>
mono- (C1-Ce) -alkylamino, di- (C:-Co) -alkylamino,<br>
hydroxyl, (C:-C$) -alkoxy, benzyloxy, carboxyl, (C1-<br>
Co)-alkoxycarbonyl, (C1-C6)-alkoxycarbonylamino or<br>
(C1-Ce)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C6-C10)-aryl<br>
and (C6-Cio)-aryl-(C1-C6)-alkyl;<br>
a 3-, 4- or 5-isoxazolyl radical or 3-, 4- or 5-<br>
isoxazolyl-(C:-C5)-alkyl radical, where the (C-:-<br>
Ce)-alkyl radical may be unsubstituted or mono- or<br>
polysubstituted by identical or different<br>
substituents from the group consisting of (C1-C6)-<br>
alkyl, halogen and oxo (=0) and the 3-, 4- or 5-<br><br>
isoxazolyl radical may be unsubstituted or mono-<br>
or disubstituted by identical or different<br>
substituencs from the group consisting of<br>
hydrogen, (C:-C6)-alkyl, halogen, nitro, amino,<br>
mono- (C1-Cs) -alkylamino, di- (C1-C6) -alkylamino,<br>
hydroxyl, (C:-C6)-alkoxy, benzyloxy, carboxyl, {Ci-<br>
Ce) -alkoxycarbonyl, (Ci~C6)-alkoxycarbonylamino or<br>
(C:-C6)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trifluoromethyl, (C6-C10)-aryl<br>
and (C6-Cio) -aryl- (C1-C6) -alkyl;<br>
a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical or<br>
1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl-(C1-C6)-alkyl<br>
radical, where the (C1-C6) -alkyl radical may be<br>
unsubstituted or mono- or polysubstituted by<br>
identical or different substituents from the group<br>
consisting of (C1-C6) -alkyl, halogen and oxo (=0)<br>
and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl<br>
radical may be unsubstituted or mono- to<br>
hexasubstituted by identical or different<br>
substituents from the group consisting of<br>
hydrogen, (C1-Ce)-alkyl, halogen, nitro, amino,<br>
mono- (C1-C6) -alkylamino, di- (C1-C6) -alkylamino,<br>
hydroxyl, (C1-Ce)-alkoxy, benzyloxy, carboxyl, (C1-<br>
Cs)-alkoxycarbonyl, (C1-C0)-alkoxycarbonylamino or<br>
(C:-C6)-alkyl which is mono- or polysubstituted by<br>
fluorine, preferably trif luoromethyl, (C6-C10) -aryl<br>
and (C6-C10)-aryl-(C1-C6)-alkyl, and also the<br>
isomers, in particular tautomers, diastereomers<br>
and enantiomers, and the pharmaceutically<br>
acceptable salts, in particular acid addition<br>
salts, thereof [lacuna].<br>
According to a further embodiment, indole derivatives<br>
of the general formula (1) are provided which are<br>
characterized in that R, R2, R3, R4, Zl and Z2 have the<br>
meanings described above and R: represents quinolyl<br>
which is mono- or polysubstituted by straight-chain or<br>
branched (C1-Cg-alkyl) or (C1-Cs) -alkoxy.<br><br>
According to a further embodiment, indole derivatives<br>
of the general - formula (1) are provided which are<br>
characterized in that R, R2, R3, R4, Zl and Z2 have the<br>
meanings described above and Ri represents 2-methyl-6-<br>
quinolyl.<br>
According to a further embodiment, indole derivatives<br>
of the general formula (1) are provided which are<br>
characterized in that R, R2, R3, R4 Zl and Z2 have the<br>
meanings described above and Ri denotes (2-methyl)-6-<br>
quinolyl, R2 denotes 4-chlorobenzyl, R3 and R4 each<br>
denote hydrogen and Zi and Z2 each denote oxygen.<br>
According to a further aspect of the invention, a<br>
process for preparing indole derivatives of the general<br>
formula (1) according to any of claims 1 to 5 is<br>
[lacuna] which is characterized in that an indole<br>
precursor of the general formula (2)<br><br>
in which R2, R3 and R4 have the meanings mentioned<br>
above is reacted with a compound of the general formula<br>
(3)<br><br><br>
in which Zl and Z2 have the meaning mentioned above and<br>
Yl and Y2 independently of one another represent a<br>
suitable leaving group, such as halogen, (C1-C6)-<br>
alkoxy, -O-tosyl, -O-mesyl or -Nl-imidazole, and then<br>
with an amine of the general formula (4) or (5)<br><br>
in which R and Rl have the meanings mentioned above,<br>
giving the desired indole derivative of the general<br>
formula (1) (with amine 4) or the compound of the<br>
general formula (6) (with amine 5)<br><br>
in which Rl, R2, R3, R4, Zl and Z2 have the meanings<br>
mentioned above, using, if appropriate, diluents and<br>
auxiliaries, where the compound of the general formula<br>
(6) may subsequently be reacted with a compound of the<br>
general formula (7)<br><br>
in which R has the meaning mentioned above and Y3<br>
represents a suitable electrophilic leaving group, such<br>
as halogen, (C1-C6)-alkoxy, -O-tosyl, -O-mesyl or -Nl-<br><br>
imidazole, giving' the desired compound (1) , where R<br>
does not denote hydrogen, using, if appropriate,<br>
diluents and auxiliaries.<br>
Synthesis routes;<br>
The compounds of the general formula 1 can be obtained<br>
according to Scheme 1 below:<br><br>
Furthermore, the compounds of the general formula 1 can<br>
also be obtained by the synthesis route of Scheme 2:<br>
Scheme 2<br><br><br>
The compounds of the general formula 1 in which R=<br>
methyl, benzyl, propargyl or cyanomethyl and Ri, R2, R3<br>
and R4 have the meanings given for the general formula<br>
1 can also be prepared according to the synthesis route<br>
of Scheme 3:<br><br>
The starting materials (2), (3) and (4) are either<br>
commercially available or can be prepared by procedures<br>
known per se. The starting materials (2), (3) and (4)<br><br>
are useful intermediates for preparing the indole<br>
derivatives of the formula (I) according to the<br>
invention.<br>
For the preparation of starting materials and target<br>
compounds, reference may be made, for example, to the<br>
following standard works of organic synthesis, the<br>
content of which is hereby explicitly included into the<br>
disclosure of the present application:<br>
1)	Houben-Weyl, Volume E 7a (part 1) pp. 290-492/<br>
pp. 571-740<br>
Houben-Weyl, Volume E 7a (part 2) pp. 119-156,<br>
pp. 205-686, pp. 157-204<br>
2)	Monograph "Heterocyclic Compounds" (Elderfield) ,<br>
Volume 1, pp. 119-207, pp. 397-616<br>
Volume 3, pp. 1-274<br>
Volume 6, pp. 101-135, pp. 234-323<br>
3)	Monograph "Comprehensive Organic Chemistry" (S.D.<br>
Barton, W.D. Ollis)<br>
Volume 4, pp. 155-204, pp. 205-232, pp. 493-564<br>
The solvents and auxiliaries to be used, if<br>
appropriate, and the reaction parameters to be used,<br>
such as reaction temperature and reaction time, are<br>
known to the person skilled in the art owing to his<br>
expert knowledge.<br>
The indole derivatives of the general formula (1)<br>
according to the invention are suitable as medicaments,<br>
in particular as antitumor agents, for treating<br>
mammals, in particular man, but also domestic animals<br>
such as horses, cattle, dogs, cats, hares, sheep,<br>
poultry and the like.<br>
According to a further aspect of che invention, a<br>
method for controlling tumors in mammals, in particular<br>
man, is provided which is characterized in that at<br>
least one indole derivative of the general formula (1)<br><br>
is administered to a mammal in an amount effective for<br>
the treatment , of the tumor. The therapeutically<br>
effective dose of the indole derivative according to<br>
the invention in question which is to be administered<br>
for the treatment depends inter alia on the nature and<br>
the stage of the oncosis, the age and the sex of the<br>
patient, the type of administration and the duration of<br>
the treatment. Administration can take place orally,<br>
rectally, buccally (for example sublingually),<br>
parenterally (for example subcutaneously, intra-<br>
muscularly, intradermally or intravenously) , topically<br>
or transdermally.<br>
According to a further aspect of the invention,<br>
medicaments for the treatment of tumors, are provided<br>
which are characterized in that they comprise, as<br>
active ingredient, at least one indole derivative<br>
according to any of claims 1 to 5 or a pharmaceutically<br>
acceptable salt thereof, if appropriate together with<br>
customary pharmaceutically acceptable auxiliaries,<br>
additives and carriers. These can be solid, semisolid,<br>
liquid or aerosol preparations. Suitable solid<br>
preparations are, for example, capsules, powders,<br>
granules, tablets. Suitable semisolid preparations are,<br>
for example, ointments, creams, gels, pastes,<br>
suspensions, oil-in-water and water-in-oil emulsions.<br>
Suitable liquid preparations are, for example, sterile<br>
aqueous preparations for parenteral administration<br>
which are isotonic with the blood of the patient.<br>
The invention is to be illustrated in more detail by<br>
the example below, without being restricted to the<br>
example.<br>
Working examples<br>
Example 1 (Reaction according to Scheme 1, 1. step):<br>
Preparation of 1-(4-chlorobenzyl)indole<br><br>
A solution of 5.86 g (0.05 mol) of indole in 25 ml of<br>
DMSO is added to a mixture of 1.32 g of sodium<br>
hydroxide (0.055 mol, suspension in mineral oil) in<br>
50 ml of dimethyl sulfoxide. The mixture is heated at<br>
60°C for 1.3 hours and then allowed to cool, and 17.7 g<br>
(0.11 mol) of 4-chlorobenzyl chloride are added<br>
dropwise. The solution is heated at 60°C, allowed to<br>
stand overnight and then poured with stirring into<br>
200 ml of water. The mixture is extracted repeatedly<br>
with a total of 75 ml of CH2CI2, the organic phase is<br>
dried with anhydrous sodium sulfate and filtered and<br>
the filtrate is concentrated under reduced pressure.<br>
Yield: 11.5 g (95% of theory)<br>
Example 2 (Reaction according to the 2. step of Scheme<br>
1) :<br>
Preparation of N-(2~methyl~6-quinolyl)-[1-(4-<br>
chlorobenzyl)indole-3-yljglyoxylamide (D-69429)<br>
At 0°C and under nitrogen, a solution of 10.2 g<br>
(42.2 mmol) of 1-(4-chlorobenzyl) indole in 50 ml of<br>
ether is added dropwise to a solution of 5.50 ml of<br>
oxalyl chloride in 50 ml of ether. The mixture is<br>
heated at reflux for 2 hours and the solvent is then<br>
evaporated. 100 ml of tetrahydrofuran were then added<br>
to the residue and the solution was cooled to -4°C and<br>
treated dropwise with a solution of 15.66 g (99.0 mmol)<br>
of 6-amino-2-methylquinoline in 350 ml of THF. The<br>
mixture is heated at reflux for 4 hours and allowed to<br>
stand at room temperature overnight. The 6-amino-2~<br>
methylquinoline hydrochloride is filtered off with<br>
suction, the precipitate is washed with THF, the<br>
filtrate is concentrated under reduced pressure and the<br>
residue is recrystallized from methyl ethyl ketone/<br>
methylene chloride.<br>
Yield: 14.8 g (77.3% of theory)<br><br>
Melting point: 182-185°C<br>
Preparation of the hydrochloride:<br>
The equivalent amount of hydrochloric acid, dissolved<br>
in isopropanol, is added to 0.453 g (1 mmol) of N-(2-<br>
methyl-6-quinolyl) - [1-^ (4-chlorobenzyl) indol-3-<br>
yl]glyoxylamide in 20 ml of hot ethanol, the mixture is<br>
heated at 70-80°C and the solution is, at 40°C and<br>
under reduced pressure, evaporated to dryness. Repeated<br>
additional evaporation with toluene gave the colorless<br>
and crystalline hydrochloride.<br>
Yield: 0.49 g (100% of theory)<br>
m.p.; 196°C<br>
Preparation of the methanesulfonate:<br>
A mixture of 0.453 g (1 mmol) of N- (2-methyl-6-<br>
quinolyl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide<br>
and 0.67 ml of methanesulfonic acid in 15 ml of<br>
dichloromethane is heated at 50°C for 30 minutes, the<br>
resulting solution is concentrated at 35°C under<br>
reduced pressure, the residue is additionally<br>
evaporated with methyl tert-butyl ether repeatedly, and<br>
the resulting residue is dried at 35°C under reduced<br>
pressure.<br>
Yield: 0.46 g (84% of theory)<br>
m.p'. : &gt; 230°C<br>
Example 3 (Reaction according to Scheme 3):<br>
Preparation of N-propargyl-N-(2-methyl-6-quinolyl)-<br>
[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide<br>
At room temperature and under nicrogen, a suspension of<br>
2.32 g (5.13 mmol) of N-(2-methyl-6-quinolyl))-[1-(4-<br>
chlorobenzyl)indol-3-yl]glyoxylamide in 20 ml of DMF is<br>
added to a suspension of 0.154 g of sodium hydride<br>
(5.13 mmol, suspension in mineral oil) in 10 ml of DMF.<br><br>
This resulted in strong foaming, with the mixture<br>
turning yellow. A solution of 0.382 g (5.13 mmol) of<br>
propargyl chloride in 10 ml of DMF is added dropwise,<br>
and the mixture is, under nitrogen gas, stirred at room<br>
temperature for 24 hours and allowed to stand at room<br>
temperature for 4 days. The dark-brown solution is then<br>
poured into 120 ml of ice water and extracted in<br>
portions with 250 ml of methylene chloride, and the<br>
combined organic phases are dried using anhydrous<br>
sodium sulfate. The extract is concentrated under<br>
reduced pressure and the residue is purified using a<br>
silica gel column (silica gel 60, from Merck AG,<br>
Darmstadt, Germany) and the mobile phase methylene<br>
chloride/ethanol (97:3, v/v).<br>
Yield: 1.98 g (78.6% of theory)<br>
Mass spectrum: m/e= 491.9 (M*)<br>
Biological tests<br>
1. Antiproliferative action in various tumor cell<br>
lines<br>
In a proliferation test, the antiproliferative activity<br>
of the substance D-69429 was examined using established<br>
tumor cell lines. In the test used, the cellular<br>
dehydrogenation activity is determined, which makes it<br>
possible to determine the vitality of the cell and,<br>
indirectly, the cell count. The cell lines used are the<br>
human cervical carcinoma cell line KB/HeLa (ATCC<br>
CCL17), the murine lymphocyte leukaemia L1210 (ATCC<br>
CCL-219), the human breast adenocarcinoma line MCF7<br>
(ATCC HTB22) and the ovary adenocarcinoma line SKOV-3<br>
(ATCC HTB77). These are established cell lines which<br>
are very well characterized and were obtained from ATCC<br>
and cultured.<br>
The results shown in Tab. 1 demonstrate the highly<br>
potent antiproliferative action of D-69429 in the cell<br><br>
lines SKOV-3, L-1210 and HeLa/KB. Owing to the<br>
particularly slow growth of the MCF7 line, the effect<br>
of D-69429 in the test period of 48 h is only small<br>
(18% inhibition at 3.16 ng/ml; thus stated as &gt;3.16).<br>
2. Method<br>
XTT Test for cellular dehydrogenase activity<br>
The adherently growing tumor cell lines HeLa/KB, SKOV-3<br>
and MCF7 and the L1210 leukaemia line, which grows in<br>
suspension, were cultivated under standard conditions<br>
in an incubator with gas inlet at 37°C, 5% C02 and 95%<br>
atmospheric humidity. On Test Day 1, the adherent cells<br>
are detached using trypsin/EDTA and pelleted by<br>
centrifugation. The cell pellet is then resuspended in<br>
the RPMI culture medium at the appropriate cell count<br>
and transferred to a 96-well microtiter plate. The<br>
plates are then cultivated overnight in the incubator<br>
with gas inlet. The test substances are made up as<br>
stock solutions in DMSO and, on Test Day 2, diluted<br>
with culture medium to the corresponding<br>
concentrations. The substances in the culture medium<br>
are then added to the cells and incubated in the<br>
incubator with gas inlet for 45 h. Cells which have not<br>
been treated with test substance serve as control.<br>
For the XTT assay, 1 mg/ml of XTT (sodium 3'-[l-<br>
(phenylaminocarbonyl) -3 , 4-tetrazolium] -bis (4-methoxy-6-<br>
nitro)benzenesulfonic acid) is dissolved in RPMI-1640<br>
medium without Phenol Red. Additionally, a 0.3 83 mg/ml<br>
solution of PMS (N-methyldibenzopyrazine methyl<br>
sulfate) in phosphate-buffered saline (PBS) is<br>
prepared. On Test Day 4, 75 ul/well of the XTT-PMS<br>
mixture are pipetted onto the cell plates, which by now<br>
have been incubated with the test substances for 4 5 h.<br>
To this end, the XTT solution is mixed with the PMS<br>
solution in a ratio of 50; i (v/v) shortly before use.<br>
The cell plates are then incubated in the incubator<br><br>
with gas inlet for a further 3 h, and the optical<br>
density (OD490nm) is determined in a photometer.<br>
Using the OD490nm obtained, the inhibition in percent<br>
relative to the control is calculated. The<br>
antiproliferative activity is estimated using<br>
regression analysis.<br><br><br><br>
Example I<br>
Tablet containing 50 mg of	active compound<br>
Composition:<br>
(1)	Active compound	50.0 mg<br>
(2)	Lactose	98.0 mg<br>
(3)	Maize starch	50.0 mg<br>
(4)	Polyvinylpyrrolidone	15.0 mg<br>
(5)	Magnesium stearate	2.0 mg<br>
Total:	215.0 mg<br>
Preparation:<br>
(1), (2) and (3) are mixed and granulated with an<br>
aqueous solution of (4). The dried granules are admixed<br>
with (5). This mixture is tabletted.<br>
Example II<br>
Capsule containing 50 mg of active compound<br>
Composition:<br>
(1)	Active compound	50.0 mg<br>
(2)	Maize starch, dried	58.0 mg<br>
(3)	Lactose powder	50.0 mg<br>
(4)	Magnesium stearate	2.0 mg<br>
Total:	160.0 mg<br>
Preparation:<br>
(1) is ground with (3) . This ground material is added<br>
with vigorous mixing to the mixture of (2) and (4).<br>
This powder mixture is, on a capsule filling machine,<br>
filled into hard gelatine capsules size 3.<br><br>
We Claim:<br>
1. The general formula (I) the substituents should at least be<br><br>
R denotes a<br>
-	hydrogen<br>
-	straight-chain or branched (C1-C6) -alkylcarbonyl<br>
-	straight-chain or branched (C1 -C6)-alkyloxycarbonyl <br>
Rl denotes<br>
-	pyrido[2,3-b]pyrazinyl<br>
-	indazolyl<br>
-	isothiazolyl<br>
-	indolyl<br>
-	isoxazolyl<br>
optionally substituted by a (C1-C6) alkyl group or (C1-C6)-alkoxy<br>
group<br>
R2 denotes benzyl, substituted with halogen<br>
R3, R4 denote hydrogen<br>
Z1,Z2 denote O,S.<br><br>
2.	Indole derivative as claimed in claim 1 wherein R, R2, R3, R4, Z1 and<br>
Z2 have the meanings described above and Rl represents quinolyl<br>
which is mono- or polysubstituted by straight-chain or branched (C1-<br>
C6-alkyl) or (C1-C6)-alkoxy.<br>
3.	Indole derivative as claimed in any of claims 1 to 2, wherein R, R2,<br>
R3, R4, Zl and Z2 have the meanings described above and R1<br>
represents 2-methyl-6-quinolyl.<br>
4.	Indole derivative as claimed in any of claims 1 to 3, wherein R, R2,<br>
R3, R4, Zl and Z2 have the meanings described above and Rl<br>
denotes (2-methyl)-6-quinolyl, R2 denotes 4-chlorobenzyl, R3 and R4<br>
each denote hydrogen and Z1 and Z2 each denote oxygen.<br><br>
5.	Indole derivative of the general formula (1) according to any of claims 1 to 4 for use as<br>
medicaments.<br>
6.	Indole derivatives of the general formula (1) to any of claims 1 to 4 is used for<br>
preparing a medicament for treating tumors in mammals.<br>
7.	Process for preparing indoles derivatives of the general formula (1) as claimed in any of<br>
claims 1 to 4 wherein an indole precursor of the general formula (2)<br><br>
in which R2, R3, and R4 have the meanings mentioned above is reacted with a<br>
compound of the general formula (3)<br><br><br>
in which Z1 and Z2 have the meaning mentioned above and Y1 and Y2<br>
independently of one another represent a suitable leaving group, such as halogen,<br>
(C1-C6) -alkoxy, -O-tosyl, -O-mesyl or -N1-imidazole, and then with an amine<br>
of the general formula (4) or (5).<br><br>
in which R and R1 have the meanings mentioned above, giving the desired<br>
compound of the general formula (1) (with amine 4) or the compound of the<br>
general formula (6) (with amine 5)<br><br><br>
in which R1, R2, R3, R4, Z1 and Z2 have the meanings mentioned above, using,<br>
if appropriate, diluents and auxiliaries, where the compound of the general<br>
formula (6) may subsequently be reacted with a compound of the general formula<br>
(7)<br><br>
in which R has the meaning mentioned above and Y3 represents a suitable<br>
electrophilic leaving group, such as halogen, (C1 -C6)-alkoxy, -O-tosyl, -O-mesyl<br>
or -N1-imidazole, giving the desired compound (1), where R does not denote<br>
hydrogen, using, if appropriate, diluents and auxiliaries.<br><br><br>
The general formula (1) the substituents should at least be<br><br>
R denotes a<br>
-	Hydrogen<br>
-	straight-chain or branched (C1-C6)-alkylcarbonyl<br>
-	straight-chain or branched (C1-C6)-alkyloxycarbonyl<br>
R1 denotes<br>
-	5-,6-, 7-quinolyl<br>
-	pyrido[2,3-b]pyrazinyl<br>
-	indazolyl<br>
-	isothiazolyl<br>
-	indolyl<br>
- isoxazolyl<br>
optionally substituted by a (C1-C6) alkyl group or (C1-C6)-alkoxy group<br>
R2 denotes benzyl, substituted with halogen<br>
R3, R4 denote hydrogen<br>
Z1, Z2 denote O, S<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzODYta29sbnAtMjAwOC1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01386-kolnp-2008-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUFCU1RSQUNUIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-ABSTRACT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUNPUlJFU1BPTkRFTkNFMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-CORRESPONDENCE1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LURFU0NSSVBUSU9OIChDT01QTEVURSkgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-DESCRIPTION (COMPLETE) 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNJRVZFRC5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMTguMS5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 18.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1rb2xucC0yMDA4LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1386-kolnp-2008-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMi0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 2-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMjYuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 26.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMjYucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gNS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 5-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0tMjctMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM-27-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUZPUk0tMjcucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LVBDVCBTRUFSQ0ggUkVQT1JULnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-PCT SEARCH REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM4Ni1LT0xOUC0yMDA4LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1386-KOLNP-2008-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMTM4Ni1rb2xucC0yMDA4LmpwZw==" target="_blank" style="word-wrap:break-word;">abstract-1386-kolnp-2008.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="250148-coating-compositions-containing-levelling-agents-prepared-by-nitroxyl-mediated-polymerisation.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="250150-security-document-with-upconverting-material.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>250149</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1386/KOLNP/2008</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>50/2011</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>16-Dec-2011</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>12-Dec-2011</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>07-Apr-2008</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ZENTARIS GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>WEISMULLERSTRASSE 50, D-60314 FRANKFURT</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>EMIG, PETER</td>
											<td>LUDWIG-ERHARDT-STR. 22, 63486 BRUCHKOBEL</td>
										</tr>
										<tr>
											<td>2</td>
											<td>AUE, BEATE</td>
											<td>VALENTIN-HOCK-STR. 32, 63762 GROSSOSTHEIS/RINGHEIM</td>
										</tr>
										<tr>
											<td>3</td>
											<td>REICHERT, DIETMAR</td>
											<td>ELSAVASTR. 79, 63863 ESCHAU</td>
										</tr>
										<tr>
											<td>4</td>
											<td>BAASNER, SILKE</td>
											<td>DITTERSDDORFER STR. 42, 61137 SCHONECK</td>
										</tr>
										<tr>
											<td>5</td>
											<td>NICKEL, BERND</td>
											<td>ALLEESTR. 35, 64367 MUHLTAL</td>
										</tr>
										<tr>
											<td>6</td>
											<td>GUNTHER, ECKHARD</td>
											<td>WINGERTSTR. 176, 63477 MAINTAL</td>
										</tr>
										<tr>
											<td>7</td>
											<td>BACHER, GERALD</td>
											<td>KRIEGERSTR. 62, 82110 GERMERING</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 401/12</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2001/008644</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2001-07-26</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>100 37 310.0</td>
									<td>2000-07-28</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/250149-novel-indole-derivatives-and-their-use-as-medicaments by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:35:50 GMT -->
</html>
